Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfatinib in advanced solid tumors
NCT02133157Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Apr 2010
- Primary completion
- Oct 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of surufatinib in solid tumor, sponsored by Hutchison MediPharma (HMP). Primary endpoint: Number of participants with adverse events. Started Apr 2010; status: completed.
02
Drugs
surufatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02133157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133157.